A case study from New Jersey ..
New Jersey became the 14th state to allow the sale of medicinal cannabis when the Compassionate Use Medical Marijuana Act was passed in 2010. Right now, more than 80,000 people in New Jersey use cannabis to treat or alleviate symptoms from 17 debilitating conditions — conditions ranging from the pain and nausea of cancer to epilepsy, ALS and glaucoma.
The New Jersey Medical Marijuana Program is enabling people to improve their quality of life, and, in some cases, to ease their end-of-life journey.
The Associated Press analyzed four states with medicinal markets that legalized recreational cannabis: Oregon, Nevada, Colorado, Alaska. All four saw a drop in medical patients after the broader legalization of cannabis. The analysis found that in Oregon the number of medical-only retail shops fell from 400 to two. Hundreds of growers who contracted with individual patients to grow specific strains ended that work.
The destruction of medicinal cannabis dispensaries in New Jersey would be tragic. As the founder of the Compassionate Care Foundation in Egg Harbor, I got to know many people who relied on medical cannabis. I spoke with veterans with Post Traumatic Stress Disorder and cancer patients who found cannabis far superior to opioids for pain relief. I met the parents of children with a rare form of epilepsy who told me of their children’s return to a normal life due to low THC cannabis. And as we continue to face an opioid epidemic, I know patients who were able to control their pain with cannabis and finally beat their opioid addictions.
The Murphy administration has been a great supporter of the medicinal marijuana program, and I am eager to work with the administration to create some protections for medicinal cannabis.
I also see the larger issues and prejudices that prevent cannabis from being treated like any other medication. In the United States, cannabis, along with heroin, is labeled a Schedule 1 drug, which means government regulators claim the drug has no currently accepted medical use and a high potential for abuse. That classification hinders the research we need to obtain a greater understanding of cannabis, such as what cannabis strains and dosages work best for certain conditions. With research lacking, physicians are less likely to recommend cannabis. Right now, insurers and payers will not cover cannabis, even for a dying cancer patient.
We created the Cannabis Education and Research Institute (CERI) to advance research and understanding around this ancient botanical, a plant that has clear healing properties. While New Jersey can create some protections for medicinal patients, ultimately we need more research and understanding. I’m urging medicinal cannabis patients to stay in New Jersey Medical Marijuana Program and to stay with their physicians.